GE HealthCare Technologies (NASDAQ:GEHC) Releases Earnings Results, Misses Expectations By $0.08 EPS

GE HealthCare Technologies (NASDAQ:GEHC) issued its quarterly earnings results on Wednesday. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.07 by ($0.08), FiscalAI reports. The company had revenue of $5.13 billion for the quarter, compared to the consensus estimate of $5.04 billion. GE HealthCare Technologies had a return on equity of 20.46% and a net margin of 9.10%.The business’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.01 EPS. GE HealthCare Technologies updated its FY 2026 guidance to 4.800-5.000 EPS.

Here are the key takeaways from GE HealthCare Technologies’ conference call:

• GE HealthCare reported a strong start to 2026 with $5.1B revenue, 2.9% organic growth, broad geographic strength (double-digit EMEA/ROW, mid-single U.S.) and a record backlog of $21.8 billion.
• Profitability disappointed in Q1 due to a PDX supplier recall (now resolved) and rising material costs, prompting management to lower full-year guidance to an adjusted EPS range of $4.80–$5.00 and reduced free cash flow to about $1.6B.
• Management quantified inflationary headwinds as roughly $250M (?$0.43/share) — ~ $100M memory chips, ~ $100M oil/freight, and ~$50M other commodities — and expects to offset more than half via price and cost actions, with most mitigation and benefits back?loaded into H2 and 2027.
• Strategic product and organizational milestones — U.S. and Japan clearances for the Photonova Spectra photon?counting CT, multiple next?gen MR FDA clearances, and the creation of a combined Advanced Imaging Solutions segment — position the company to accelerate adoption of high?margin NPIs that should begin contributing revenue in 1H 2027.
• Progress in Pharmaceutical Diagnostics includes Flyrcado ramping (~80% dose increase since late January, 390 doses the week of April 17) on a path to management’s $500M+ 2028 target, accelerating Vizamyl demand, and a manganese?based, gadolinium?free MRI contrast now in combined Phase II/III with FDA Fast Track status.

GE HealthCare Technologies Stock Performance

GEHC traded up $0.23 during trading on Friday, reaching $61.07. 8,699,220 shares of the company were exchanged, compared to its average volume of 3,939,107. GE HealthCare Technologies has a 52 week low of $58.75 and a 52 week high of $89.77. The company has a current ratio of 1.22, a quick ratio of 1.13 and a debt-to-equity ratio of 0.95. The firm has a 50 day moving average of $73.28 and a 200 day moving average of $77.52. The stock has a market cap of $27.87 billion, a P/E ratio of 14.62, a PEG ratio of 1.34 and a beta of 1.17.

GE HealthCare Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Friday, April 3rd will be given a dividend of $0.035 per share. The ex-dividend date is Thursday, April 2nd. This represents a $0.14 dividend on an annualized basis and a yield of 0.2%. GE HealthCare Technologies’s payout ratio is currently 3.35%.

Insider Buying and Selling at GE HealthCare Technologies

In related news, CEO Peter J. Arduini bought 4,169 shares of the business’s stock in a transaction on Thursday, April 30th. The shares were bought at an average cost of $59.92 per share, for a total transaction of $249,806.48. Following the completion of the purchase, the chief executive officer owned 259,424 shares of the company’s stock, valued at $15,544,686.08. This represents a 1.63% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James Saccaro purchased 3,310 shares of the stock in a transaction dated Friday, May 1st. The shares were purchased at an average price of $60.60 per share, with a total value of $200,586.00. Following the transaction, the chief financial officer directly owned 87,471 shares of the company’s stock, valued at approximately $5,300,742.60. The trade was a 3.93% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have purchased 9,229 shares of company stock worth $556,180. 0.36% of the stock is owned by insiders.

Institutional Investors Weigh In On GE HealthCare Technologies

Several large investors have recently made changes to their positions in the company. Empowered Funds LLC raised its holdings in shares of GE HealthCare Technologies by 6.1% during the first quarter. Empowered Funds LLC now owns 28,848 shares of the company’s stock valued at $2,328,000 after buying an additional 1,665 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of GE HealthCare Technologies in the 1st quarter worth approximately $259,000. Cresset Asset Management LLC raised its holdings in shares of GE HealthCare Technologies by 12.5% in the 2nd quarter. Cresset Asset Management LLC now owns 7,802 shares of the company’s stock worth $578,000 after purchasing an additional 865 shares in the last quarter. Jump Financial LLC raised its holdings in shares of GE HealthCare Technologies by 317.6% in the 2nd quarter. Jump Financial LLC now owns 28,132 shares of the company’s stock worth $2,084,000 after purchasing an additional 21,396 shares in the last quarter. Finally, Gamco Investors INC. ET AL lifted its stake in GE HealthCare Technologies by 8.6% during the second quarter. Gamco Investors INC. ET AL now owns 4,041 shares of the company’s stock valued at $299,000 after purchasing an additional 320 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Citigroup cut their price objective on GE HealthCare Technologies from $80.00 to $65.00 and set a “neutral” rating on the stock in a research note on Thursday. JPMorgan Chase & Co. lowered their price target on GE HealthCare Technologies from $80.00 to $65.00 and set a “neutral” rating for the company in a report on Thursday. Wells Fargo & Company dropped their price target on GE HealthCare Technologies from $97.00 to $75.00 and set an “overweight” rating on the stock in a research report on Thursday. UBS Group cut GE HealthCare Technologies from a “neutral” rating to a “sell” rating and raised their price objective for the stock from $73.00 to $77.00 in a research note on Thursday, January 15th. Finally, Mizuho lowered their target price on shares of GE HealthCare Technologies from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $80.67.

GE HealthCare Technologies News Roundup

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Insiders buying: multiple company insiders increased holdings (CEO Peter Arduini, CFO James Saccaro, and director Frank R. Jimenez), signaling management confidence and providing technical support to the stock. Forms filed with the SEC show the recent buys. Read More. Read More. Read More.
• Positive Sentiment: Unusual options activity: heavy call buying (?19,200 calls, ~448% above average) suggests traders are positioning for a rebound or event-driven upside in the near term.
• Neutral Sentiment: Operational/strategic updates: GEHC reorganized imaging businesses (creating an Advanced Imaging Solutions unit) and made executive changes to improve execution — strategic but benefits likely play out over multiple quarters. Read More.
• Neutral Sentiment: Mixed analyst actions: some firms kept constructive ratings with lower targets (e.g., Wells Fargo kept an overweight rating but cut its PT to $75), indicating medium?term upside tempered by nearer?term risks. Read More.
• Negative Sentiment: Guidance cut / margin pressure: management trimmed FY26 EPS to $4.80–$5.00 and cited inflation, higher component/logistics costs and supplier issues — the primary catalyst for the recent sell?off. Read More.
• Negative Sentiment: Mixed Q1 results: revenue beat (~$5.13B, +7.4% y/y) but EPS missed ($0.99 vs. $1.07 est.) and margins compressed, reinforcing short?term downside risk until execution and cost trends improve. Read More.
• Negative Sentiment: Analyst cuts / downgrades: several shops trimmed price targets and/or ratings (Citigroup, JPMorgan and others reduced targets to around the mid?$60s), increasing near?term selling pressure. Read More.
• Negative Sentiment: Litigation risk: a shareholder law?firm inquiry (Johnson Fistel) into executive conduct introduces headline and legal risk that can amplify volatility. Read More.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.